Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...

A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a ...

Weight-loss drugs have been found to dramatically slash death rates in colon cancer patients, according to new research. Patients taking GLP-1 receptors - the class of drugs behind Ozempic, Wegovy and ...

Researchers at the University of Colorado Anschutz may have identified why many cancer patients say food suddenly tastes ...

GLP-1s were linked to a lower death risk in colon cancer in a recent study. Image credit: ARMEND NIMANI/Getty Images “This means that, “in addition to lowering glucose [blood sugar] and weight, they ...

Breast cancers driven by a particular genetic signature can already be treated by a particular class of targeted therapies, but the race is on to develop next-generation medicines that improve the ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...